Vanguard Global Advisers
TARS icon

Vanguard Global Advisers’s Tarsus Pharmaceuticals TARS Stock Holding History

Vanguard Global Advisers’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$941K Sell
14,946
-1,481
-9% -$94.6K ﹤0.01% 1783
2026
Q1 		$1.15M Buy
+16,427
New +$1.15M ﹤0.01% 1561

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Global Advisers's TARS Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Tarsus Pharmaceuticals (TARS) stake by 9% in Q2 2026, selling an estimated $94.6K and leaving 14,946 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #1783.

Vanguard Global Advisers first reported a position in TARS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.15M in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Vanguard Global Advisers held 14,946 shares of Tarsus Pharmaceuticals worth $941K as of Q2 2026.
  • Vanguard Global Advisers sold 1,481 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $94.6K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1783 holding.
  • Vanguard Global Advisers first reported a position in Tarsus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Tarsus Pharmaceuticals position peaked at $1.15M in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.